Lisata Therapeutics (LSTA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$100,000.00

Revenue (quarter)

—

Revenue growth (year over year)

−100.00%

Gross profit (trailing twelve months)

$100,000.00

Gross margin

100.00%

Net income (trailing twelve months)

−$14.6M

Net income (quarter)

−$2.9M

Net income growth (year over year)

+37.13%

Net margin

−14621.00%

Return on equity

−99.89%

EPS (trailing twelve months)

−$1.64

Book value per share

$0.90

P/E (trailing twelve months)

—

Price to book

1.16

Debt to assets

27.54%

Payout ratio

—

Dividend yield

—

Company profile

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.

• Is Lisata Therapeutics (LSTA) profitable?

  No. Lisata Therapeutics reported a net loss of $14.6M over the trailing twelve months.

• How much revenue does Lisata Therapeutics (LSTA) make?

  Lisata Therapeutics generated $100,000.00 in revenue over the trailing twelve months, down 100.00% year over year.

• How do I buy stock in Lisata Therapeutics (LSTA)?

  LSTA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.